聯生藥 UB-221 scores success in Phase 2 Chinese urticaria trial; plans to launch Phase 3 and overseas Phase 2 food allergy trials - Global Bio & Investment Monthly
Published ・ Source Taiwan | 環球生技月刊
Summary not yet available
Facts
Phase 2 clinical trial for chronic spontaneous urticaria
中山醫大 launches Taiwan-Japan care technology innovation hub, linking industry, academia and medicine to bring technology into practice - Global Bio & Investment Monthly